The LORIS Trial: Addressing overtreatment of ductal carcinoma in situ

Clinical Oncology

Volumn 27, Issue 1, 2015, Pages 6-8

  Francis, A ^a   Fallowfield, L ^b   Rea, D ^c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; EDITORIAL; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MASTECTOMY; MORBIDITY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; TUMOR INVASION; UNITED KINGDOM;

EID: 84964289642     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.09.015     Document Type: Editorial

References (21)

1. Jorgensen K.J., Keen J.D., Gotzsche P.C. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality?. Radiology 2011, 260(3):621-627.
2. Kopans D.B., Smith R.A., Duffy S.W. Mammographic screening and "overdiagnosis". Radiology 2011, 260(3):616-620.
3. http://www.cancerresearchuk.org/cancer/info/cancerstats/types/breast/Incidence-in-situ/.
4. [accessed 05.01.14]. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/.
5. NHS Breast Screening Programme and Association of Breast Surgery An audit of screen detected breast cancers for the year of screening April 2012 to March 2013 PHE 2014.
6. Fallowfield L., Matthews L., Francis A., et al. Low grade ductal carcinoma in situ (DCIS): how best to describe it?. Breast 2014, 23:693-696.
7. Van Gestel Y.R., Voogd A.C., Vingerhoets A.J., et al. Acomparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 2007, 43(3):549-556.
8. Fallowfield L., Francis A., Catt S., et al. Time for a low-risk DCIS trial: harnessing public and patient involvement. Lancet Oncol 2012, 13(12):1183-1185.
9. Lasagana Modern Hippocratic oath 1964.
10. Gotzsche P.C., Jorgensen K.J. The breast screening programme and misinforming the public. JR Soc Med 2011, 104(9):361-369.
11. Independent UK Panel on Breast Cancer Screening The benefits and harms of breast cancer screening: an independent review. Lancet 2012, 380(9855):1778-1786.
12. Marmot M., Altman D.G., Cameron D., et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013, 108(11):2205-2240.
13. Weigel S., Heindel W., Heidinger O., et al. Digital mammography screening: association between detection rate and nuclear grade of ductal carcinoma in situ. Radiology 2014, 271(1):38-44.
14. Francis A., Bartlett J.M.S., Billingham L.J., et al. The LORIS trial: a multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ. Cancer Res 2013, 73(supp). OT2-3-01.
15. Wallis M.G., Clements K., Kearins O., et al. The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 2012, 106(10):1611-1617.
16. Bombonati A., Sgroi D.C. The molecular pathology of breast cancer progression. JPathol 2011, 223(2):307-317.
17. Meijnen P., Peterse J.L., Antonini N., et al. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 2008, 98(1):137-142.
18. Parham D.M., Coleman D., Kodikara S., et al. The NHS breast screening programme (pathology) EQA: experience in recent years relating to issues involved in individual performance appraisal. JClin Pathol 2006, 59(2):130-137.
19. Shrestha D.B., Schneiders M., Ravichandran D., et al. Ductal carcinoma in situ of the breast: is clinical follow-up necessary after treatment. Clin Oncol 2013, 25:445.
20. Allen M.D., Luong P., Hudson C., et al. Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of alphavbeta6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clin Cancer Res 2014, 20(2):344-357.
21. Solin J., Gray R., Baehner F.L. Amultigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. JNatl Cancer Inst 2013, 105(10):701-710.